GA
PCRX icon

GoalVest Advisory’s Pacira BioSciences PCRX Stock Holding History

GoalVest Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-70
Closed -$2.15K – 461
2023
Q3 		$2.15K Buy
70
+4
+6% +$144 ﹤0.01% 420
2023
Q2 		$2.65K Buy
+66
New +$2.73K ﹤0.01% 338

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

GoalVest Advisory's PCRX Position: Q4 2023 in Review

GoalVest Advisory sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 70 shares — an estimated $2.15K sold.

GoalVest Advisory first reported a position in PCRX in Q2 2023 and held it in 2 quarters. The position peaked at $2.65K in Q2 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

  • GoalVest Advisory reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
  • GoalVest Advisory sold 70 Pacira BioSciences shares in Q4 2023, an estimated $2.15K.
  • GoalVest Advisory first reported a position in Pacira BioSciences in Q2 2023 and held it in 2 quarters.
  • GoalVest Advisory's Pacira BioSciences position peaked at $2.65K in Q2 2023.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on GoalVest Advisory's 13F filing for Q4 2023, filed 2 Jan 2024.